Close Menu

NEW YORK – Precision medicine startup Curesponse has raised $6 million in a Series A financing round with participation from investors including London-based NCL Technology Ventures and Israel-based aMoon.

The Rehovot, Israel-based precision medicine firm will use the funding to scale clinical trials for its cResponse functional cancer testing platform and expansion to the UK.

Curesponse's cResponse platform preserves a patient's tumor in 3D for up to two weeks, allowing users to observe the cancer microenvironment's response to cancer therapies.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.


Join this webinar to learn how spatial resolution of gene expression in tumor tissue reveals new insights in biomarker discovery and therapeutic response. 


This webinar will discuss a study that set to assess the efficacy and safety of osimertinib in EGFR T790M positive non-small cell lung cancer (NSCLC) patients identified by using plasma sample and cobas EGFR Mutation test v2. This is the first prospective study to use liquid biopsy upfront to evaluate osimertinib efficacy.


Non-small cell lung cancer (NSCLC) patients with ALK rearrangements are treated with tyrosine kinase inhibitors (TKIs), which often leads to prolonged overall survival. However, treatment resistance will almost inevitably occur, and the disease remains incurable.